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Lalitha Sivaswamy, MD
Objective.—This study aims to compare the management practices of a headache specialist with non-headache specialists 
in the treatment of children with migraine. The use of appropriate rescue medications and prophylactic agents, application of 
neuroimaging, and short-term outcomes are compared in children treated by the two groups of physicians.
Methods.—A retrospective cohort study was conducted by utilizing the electronic medical records of children 3-18 years of 
age with migraine, who were evaluated at a tertiary care children’s hospital from 2016 to 2018.
Results.—Of the 849 patients who met the study criteria, 469 children were classified as having chronic migraine or high-
frequency episodic migraine and were followed-up on at least 1 occasion by the neurologists. Imaging was obtained in 66.5% 
of all children with migraine. The headache specialist used 5-HT agonists (“triptans”) for migraine management in 56.7% 
(76/135) of cases compared to non-headache specialists who prescribed them in 28.7% (96/334) of cases (P  <  .001). Of the 
children with chronic migraine, the headache specialist evaluated 135 patients while the non-headache specialists treated 334 
children. Non-headache specialists prescribed prophylaxis in the form of natural supplements more frequently (63.8% of cases) 
compared to the headache specialist (38.5% of children) (P  <  .001). Moreover, prophylaxis with prescription drugs was utilized 
more often by headache specialist (66.7%) than non-headache specialists (37.4%) (P  <  .001).
Conclusions.—Imaging appears to be commonly recommended by both headache specialists and non-headache specialists in 
children with migraine. The headache specialist was more likely to use triptans as rescue medications for pediatric migraine. 
Outcomes in the short-term were not statistically different whether children were being managed by the headache specialist or 
the non-headache specialists.
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INTRODUCTION
Migraine is a common disorder in children, af-
fecting 4 to 11% of  those between 7 years and 11 
years of  age, and 8 to 23% of  adolescents.1 Since the 
disorder is widely prevalent, it would stand to rea-
son that the bulk of  care to children with migraine 
would be provided by primary care physicians, as it 
is in adults. Only a small percentage of  adults with 
migraine is referred to a neurologist or headache spe-
cialist.2,3 However, as medicine continues to become 
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specialized, there is evidence that children with cer-
tain conditions, for example, epilepsy, who are eval-
uated at tertiary care centers have better outcomes.4 
Similarly, there is some indication that adults who 
have access to a headache specialist can manage their 
symptoms more effectively and have greater satisfac-
tion.5 Use of  appropriate rescue medications such as 
5-hydroxytryptamine agonists (commonly referred to 
as triptans) seem to be more widely prescribed by neu-
rologists.6 On the whole, migraine is often underdiag-
nosed and therefore undertreated in various parts of 
the world.7
The primary purpose of this study is to compare 
the management practices of child neurologists who 
are not headache specialists, with a pediatric head-
ache specialist at a tertiary care children’s hospital. 
We hypothesize, a priori, that the headache specialist 
would offer effective abortive options and start evi-
dence-based prophylaxis, when indicated, at a higher 
rate. We propose that when care is provided by a head-
ache specialist, there is more judicious use of neuro-
imaging. Finally, at short-term follow-up, we propose 
that children evaluated in the headache clinic would 
have fewer headache days.
As a secondary objective, we aim to describe the 
demographics of the population referred for evalua-
tion of migraine to a tertiary care institution.
PATIENTS AND METHODS
A retrospective cohort study was conducted using 
the electronic records of children who were evaluated 
at the general neurology or headache clinics of the 
Children’s Hospital of Michigan (Detroit, MI) from 
2016 to 2018. The total number of referrals to the out-
patient neurology clinic is approximately 14,000 per 
year. The overwhelming majority of children who are 
evaluated in the neurology department are referred by 
their pediatricians, with very few parents requesting an 
appointment on their own. Prior to initiating the study, 
we obtained written approval from the Institutional 
Review Board of Wayne State University School of 
Medicine. Consent and Assent was waived by the 
Institutional Review Board due to the retrospective na-
ture of the study. This is a primary analysis of the data 
set with no prior publications available that report the 
results of this data set.
STUDY SETTING
The department of child neurology at the study site 
consists of 1 headache specialist (LS) who runs a head-
ache clinic in conjunction with mid-level providers and 
eight child neurologists, who have other areas of ex-
pertise (non-headache specialists). Mid-level providers 
evaluate and treat patients solely under the guidance of 
the supervising physician. The general neurology clinics 
for the purposes of this study are defined as those clinics 
staffed by the non-headache specialists. The headache 
specialist is board certified in Headache Medicine by 
the United Council of Neurologic Specialties. Patients 
are usually scheduled to be followed-up 3 months after 
their initial visit. Due to a large number of referrals for 
headache, not all children are evaluated in the head-
ache clinic. Whether the child is evaluated in the head-
ache clinic or by a non-headache specialist depends on 
who referring physician requests, patient preference, 
and availability of appointment slots. For instance, the 
referring physician may request that the patient be seen 
at the earliest, in which case the child would most likely 
be scheduled with a non-headache specialist. In most 
instances, requests for evaluation of headache are not 
actively triaged by a nurse or physician. The headache 
specialist uses a structured template for evaluation and 
documentation.
STUDY POPULATION
Children from 3 years to 18 years of age who were 
evaluated at the Children’s Hospital outpatient gen-
eral neurology or headache clinics and given a primary 
diagnosis of migraine with aura, migraine without 
aura, or chronic migraine were included for analysis. 
Children with migraine variants, such as cyclical vom-
iting and abdominal migraine, were excluded. For de-
scriptive analysis, we created a database of outpatient 
neurology visits that included the above diagnoses.
We examined the characteristics of the study co-
hort with respect to (1) patient demographics including 
age, gender, and race and residential status, ie, urban 
vs suburban. Postal zip codes which encompassed a 
10-mile radius from the hospital and located within 
the city limits of Detroit were classified as urban; (2) 
clinical features including duration to seek a neurology 
consult and duration of symptoms prior to being re-
ferred to a neurologist. To give better context for our 
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descriptive data, we also examined the most common 
comorbidities including obesity, snoring, seizures, and 
psychiatric conditions, such as attention deficit hyper-
activity disorder and attention deficit disorder.
The ICHD-3 (International Classification of 
Headache Disorders) criteria were applied to estab-
lish a diagnosis of acute and chronic migraine. While 
ICD-9 codes were utilized to create the database, each 
record was reviewed individually by the research as-
sistants and only those who met the ICHD-3 criteria 
for migraine were ultimately used in the study. In the 
event of ambiguity regarding the diagnosis or when a 
child had more than 1 type of headache, the headache 
specialist reviewed the record to establish a definitive 
diagnosis and decide whether to include the record in 
the database. Since some children were in the preschool 
age group, it was necessary to use the best judgment 
of the headache specialist to classify these children’s 
symptoms as “most likely” to be migraine.
Comparisons between the treatment offered by the 
headache specialist and non-headache specialists fo-
cused on three variables: use of triptans, use of prophy-
lactics which was dichotomized into nutraceuticals or 
prescription drugs (or both), and short-term follow-up 
outcomes using a single measure, ie, headache-free 
days.
STATISTICAL DATA ANALYSIS
No statistical power calculation was conducted 
prior to the study. The sample size was based on the 
available data and the number of children who were 
evaluated at the study site during the study period 
that was agreed upon by the co-authors. The data are 
summarized and reported with categorical variables 
by numbers and percentages. The normality of con-
tinuous variables is tested by Shapiro-Wilk test. We 
described non-normally distributed continuous vari-
ables by Medians and Interquartile Ranges. Pearson’s 
Chi-squared test was used to analyze the distribution 
of categorical variable by groups, provided no expected 
frequency less than one, and no more than 20% of the 
cell should have an expected frequency less than five, 
otherwise Fisher’s exact test is used for the analysis. SAS 
(version 9.4, SAS Institute Inc. Cary, North Carolina) 
was used to perform statistical analyses. Significance 
level was set at .05. A 2-tail test was used to test the 
significance of null hypothesis for its rejection/accept-
ance at both sides of the sampling distribution of test 
statistic. Cohen’s Kappa of .70 was noted during tests 
of inter-rater reliability for categorical variables.
RESULTS
The demographics of  the study population and 
co-morbidities are listed in Table 1. Age ranges of  the 
children who were analyzed is depicted in Figure 1. 
A total of  1215 electronic charts were available for 
review, of  which 849 who met the criteria for analy-
sis and 366 records were excluded due to inadequate 
documentation, not meeting ICHD criteria or being 
outside the age range for the study. See Figure 2  
for flow diagram of  the study sample. Out of  the 
study sample of  849 records, 469 met the criteria for 
chronic migraine /high frequency episodic migraine 
and had at least 1 follow-up visit following the index 
visit. High-frequency episodic migraine was defined 
as migraine that occurs less frequently (typically 
Table 1.—Sociodemographic Features of  All Children With Migraine N = 849




Gender Female 472 (55.6%) Male 377 (44.4%)
Race Black 255 (30.0%) White 307 (36.2%) Hispanic 28 (3.3 %) Other 259 (30.6%)








10-14 headache days per month) than chronic mi-
graine but nonetheless imposes significant disability 
on the individual.8 While most studies of  individuals 
with migraine have a female predominance, we had 
an almost equal proportion of  males and females 
probably due to the fact that we included prepu-
bertal children as well. We had a statistically equal 
representation of  African American, Caucasian, and 
children from “other” races in our cohort. There was 
also a statistically equal representation of  children 
from urban and suburban locations.
In our study group, 46.6% (395/849) of children 
were referred to the neurology department for more 
than a year after the onset of migraine. About 19% of 
patients consulted with a neurologist between 6 and 12 
months (161/849), 9.2% (78/849) were evaluated by a 
neurologist between 4 and 6 months, and only in 17.5% 
(149/849) of cases, it was a consultation obtained in less 
than 4 months. With 7.5% (63/849) of patients, it was 
unknown how long it took to access a child neurologist 
after the onset of migraine as the parents and children 
could not recall the onset of symptoms. The time to see 
a headache specialist was not separately analyzed.
We compared the rate of imaging, treatment mo-
dalities, and outcomes for children who were treated by 
the headache specialist with those being treated by the 
non-headache specialists. The results of these findings 
are outlined in Table 2.
Imaging, in the form of MRI in almost all in-
stances, was obtained in 66.5% (564/849) of all chil-
dren with migraine. Of the children who had imaging, 
in 18.1% (102/564) of cases, it was ordered by the 
primary care physician. Normal imaging findings 
were noted in 59.2% (334/564) of cases who had an 
Fig. 1.—Age distribution of patient population. [Color figure can be viewed at wileyonlinelibrary.com]
Fig. 2.—Flow diagram of the study group. [Color figure can be 
viewed at wileyonlinelibrary.com]
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MRI, and incidental findings (arachnoid cysts, small 
pineal cysts, hypoplastic venous sinuses, developmen-
tal venous anomalies, and small bright signals on T2 
imaging) were noted in 37.9% (214/564) of children. 
Findings that would lead to a diagnosis other than mi-
graine and considered clinically significant were noted 
in 2.4% (14/564). We considered bright signals on T2 
to be an incidental finding as it has been described in 
individuals with migraine.9,10 Children evaluated by a 
headache specialist received imaging at similar rates as 
those cared for by a non-headache specialist, ie, 68.9% 
vs 74.2% (95%CI: −15.0%, 4.3%; P = .238). None of 
the children with clinically significant findings on MRI 
had focal neurological findings such as papilledema, 
ataxia, or cranial nerve palsies.
On the whole, triptans were prescribed in 30.3% 
(257/849) of all children in the study cohort. Children 
referred to the care of a headache specialist received 
triptans in 56.7% (76/135) of cases compared to 
non-headache specialists who prescribed them in 28.7% 
(96/334) of cases (95%CI: 18.1%, 38.5%; P < .001).
Of the total cohort of 849 patients, 469 children 
were diagnosed with chronic migraine/high-frequency 
episodic migraine and evaluated 2 or more times by 
either the headache specialist or the non-headache spe-
cialists, ie, an index visit and at least 1 follow-up visit. 
The headache specialist managed 135 patients while 
the non-headache specialists treated 334 children of the 
469 children with chronic migraine/high-frequency epi-
sodic headache. We did not include children who were 
initially evaluated by the non-headache specialist and 
were subsequently referred to the headache specialist. 
We did not match patients seen by the headache and 
non-headache specialist by age, gender, race, or pres-
ence/absence of co-morbidities and most importantly 
severity of their disease. However, the two groups were 
fairly comparable with respect to demographics as can 
be seen in Tables 3 and 4. Of all children with chronic 
migraine/high-frequency episodic migraine, 82.1% 
(385/469) were started on prophylaxis after referral to 
the tertiary care hospital. In situations where prophy-
laxis was warranted (which in our center primarily in-
cludes chronic migraine or high-frequency migraine as 
defined above), the non-headache specialists started the 
patient on a daily regimen in 87.4% of cases (293/334), 
whereas the headache specialist prescribed prophylaxis 
at a rate of 91.8% (123/135) (P = .17). Prophylaxis in 
the form of natural supplements (most commonly ribo-
flavin, butterbur, and coenzyme Q10) was preferred by 
the non-headache specialists 63.7% (212/334) vs 38.7% 
(52/135) for the headache specialist (95%CI: −35.4%, 
−15%; P  <  .001). Moreover, prophylactic drugs were 
prescribed by the headache specialist in more instances 
(66.7%, ie, 90/135 vs 37.4%, ie, 125/334 with 95%CI: 
19.2%, 39.3%; P  <  .001). The most commonly used 
medication in children younger than 10 years of age 
was cyproheptadine. Children over the age of 10 years 
were prescribed as topiramate, cyproheptadine, and 
amitriptyline, either individually or in combination, in 
most cases. A few children were treated by the head-
ache specialist with lamotrigine, sodium valproate, pro-
pranolol, gabapentin, and/or verapamil. At our center 







95% CI for the Difference in 
Proportion
Imaging 93 (68.9%) 248 (74.2%) .238 (−15.0%, 4.3%)
Triptan use 76 (56.7%) 96 (28.7%) <.001 (18.1%, 38.5%)
Use of natural supplement for 
prophylaxis
52 (38.7%) 212 (63.7%) <.001 (−35.4%, −15%)
Use of prescription drugs for 
prophylaxis
90 (66.7%) 125 (37.4%) <.001 (19.2%, 39.3%)
Short-term outcome of treatment
No significant improvement 36 (26.7%) 74 (22.2%) .483 (−4.7%, 13.7%)
Mild to moderate improvement 63 (46.7%) 150 (44.7%)
Significant improvement 36 (26.3%) 108 (32.3%)
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by consensus opinion, prophylaxis is usually started in 
children with chronic migraine or high-frequency epi-
sodic migraine.
Finally, outcomes between children treated by the 
headache specialist vs the non-headache specialists 
were compared using a single parameter, ie, headache- 
free days. Outcomes were classified as no improve-
ment (less than 25% reduction in the frequency of 
headache days), mild to moderate improvement 
(25% to 50% reduction in the frequency of  headache 
days), and significant improvement (more than 50% 
reduction in headache days). The mean follow-up 
period was 3 months since the first visit. No statis-
tically significant differences were noted in children 
evaluated by the headache specialist vs non-head-
ache specialist with respect in mild/moderate im-
provement or significant improvement in headache.
DISCUSSION
We retrospectively analyzed the electronic health 
records of a sample of children with migraine who 
were referred for neurological evaluation to a tertiary 
care children’s hospital.
Certain interesting patterns were noted in our co-
hort. First, it appears that about half  of all children 
were referred more than a year after the onset of chronic 
migraine. While waiting for the neurology referral, less 
than 5% of children who qualified for the use of pro-
phylactics were started on preventive medications. No 
child was prescribed as a triptan by their primary care 
physician. While no clear data exists regarding who 
provides the bulk of care for children with migraine in 
the United States, a recent study of drug use in chil-
dren with migraine suggests that slightly more than 
half  of these children are cared for by pediatricians, 




Non- Headache Specialist 
(N = 334) P-Value
95% CI for Difference in 
Mean/ Proportion
Age
Mean 12.8 ± 3.5 12.2 + 3.6 .774 (−0.111, 1.313)
Median 14.0 13.0
Gender (female) 73 (54.8%) 189 (56.4%) .818 (−12.2%, 8.8%)
Race
Black 48 (36.1%) 112 (33.8%) .676 (−7.6%, 1.27%)
White 58 (43.6%) 141 (42.2%) .864 (−9.1%, 1.19%)
Hispanic 6 (4.5%) 10 (3%) .595 (−3.0%, 6.0%)
Others 21 (15.8%) 71 (21.0%) .226 (−13%, 2.7%)
Obesity 46 (34.6%) 146 (43.7%) .088 (−19.3%, 1.1%)
OSAS 6 (4.5%) 30 (9.0%) .149 (4.5%, 0.7%)
Seizures 5 (3.8%) 24 (7.2%) .241 (−8%, 1.4%)
Psychiatric conditions  
(depression, anxiety, ADHD)
10.5% (14/133) 13.8% (46/334) .428 (−10.2%, 3.7%)
Table 4.—Age Ranges of  Children Evaluated by Headache Specialist vs. Non-Headache Specialist
Age Headache Specialist (N = 133) Non-Specialist (N = 334) P-Value
3-5 years age 2 (1.5%) 9 (2.7%)
.774
6-8 years age 13 (9.8%) 43 (12.9%)
9-11 years age 32 (24.1%) 73 (21.9%)
12-14 years age 30 (22.6%) 76 (22.8%)
15-17 years age 46 (34.6%) 116 (34.7%)
18-20 years age 10 (7.5%) 17 (5.1%)
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about 25% receive care from a combination of family 
medicine and “other” physicians, and less than a quar-
ter are treated by a neurologist.2 Undertreatment of 
migraine is widely prevalent, per reported literature, in 
both adults and children with a third of children with 
migraine receiving no prescription drugs during their 
neurology office visit.2 It is thought that about 50% of 
individuals with migraine can self-manage their symp-
toms, with non-prescription drugs.11 Those who fail 
over-the-counter medications would be the ones who 
benefit from prophylaxis and the use of more effective 
rescue medications. Even adults treated by headache 
specialists may be under treated with low access to 
rescue medications and prophylaxis. Adults who were 
seen by a specialist in Europe with migraine received 
a triptan in 4-20% of instances.12,13 A similar study in 
the United States by Lewis et al noted that only 50% 
of children with chronic migraine who are eligible for 
prophylactic options, evaluated at a pediatric neurol-
ogy clinic, received prophylaxis.14 While one cannot 
conclude from the current study that outcomes were 
better for children who were treated by neurologists 
vs primary care physicians, it does appear that in our 
cohort, neurologists were proactive in utilizing prophy-
lactic agents and using more effective rescue agents.
Second, imaging was obtained in about two-
thirds of  children, despite a diagnosis of  migraine. It 
is well-documented that imaging is not helpful in the 
vast majority of  children with a non-traumatic head-
ache unless they have a focal neurological finding.15 
However, it appears that child neurologists have a low 
threshold for obtaining brain imaging, with imaging 
rates greater than pediatric emergency department 
physicians or primary care physicians.16 In most in-
stances, though it was rarely documented as such in 
the records, it appears that imaging was obtained in 
our patients purely for parental concerns. The per-
centage of  children with a concerning physical find-
ing on examination or who experienced what was 
considered as an atypical migraine pattern was less 
than 10% in our cohort. This rate of  imaging is com-
parable to other studies wherein children with head-
ache were evaluated by a neurologist.17 Significant 
findings that necessitated a change in treatment plan 
were only found in 2.4 % of  children, with a signifi-
cant minority of  children having incidental findings 
that did not influence treatment decisions. Our study 
reiterates that imaging is overused in the evaluation 
of  a pediatric migraine, even by the very group of 
physicians who are involved in putting forth practice 
parameters that advise against it. Interestingly, there 
was no statistically significant difference in neuroim-
aging rates between the headache specialist and the 
non-headache specialists.
COMPARISON OF CARE RECEIVED  
FROM NON-HEADACHE SPECIALIST  
VS HEADACHE SPECIALISTS
The most striking difference between treatment 
strategies employed by non-headache specialists vs 
the headache specialist was in the use of  triptans. 
Non-headache specialists prescribed triptans 28.7% 
of  the times while the headache specialist used a fre-
quency of  56.7%. Nonetheless, on the whole, only 
30.3% of  all children with migraine were prescribed 
a triptan.
Effective treatment of  exacerbations is an im-
portant goal for patients and families. Non-steroidal 
anti-inflammatory drugs (NSAIDs) were widely 
used by children in our cohort prior to being eval-
uated by neurologists. Ibuprofen and acetamino-
phen are statistically more effective than placebo in 
children, have an acceptable side effect profile, and 
are easily accessible, thereby making them natural 
first-line drugs for abortive use.18 However, serotonin 
5-hydroxytryptamine agonists (“triptans”) are indi-
cated for children who do not respond effectively to 
NSAIDs. Several triptans including rizatriptan and 
zolmitriptan have been studied in children as young 
as 6 years of  age, are tolerated well in most instances, 
and offer relief  in about 70% of  children.19,20 Aspirin 
and opiates were not used by any patients in our co-
hort. While the headache specialist utilized triptans 
more than the non-headache specialists, the lack 
of  matching in terms of  chronicity and intensity of 
symptoms between children evaluated by the two 
groups of  physicians precludes us from conclusively 
stating that the headache specialists used them more 
often because they were more aware of  the indica-
tions. It does appears that the headache specialist 
in our study was more familiar with the indications 
for triptans in children and indeed offered them at 
October 20191544
significantly higher rates than non-headache spe-
cialists. However, even children being treated by the 
headache specialist were primarily prescribed oral 
sumatriptan that has low bioavailability and possibly 
low efficacy.21,22 The second-line triptan used in our 
headache clinic was oral rizatriptan. These choices 
were determined by insurance coverage. Almotriptan 
and nasal zolmitriptan, which are FDA approved in 
adolescents, were not prescribed in any instance, even 
by the headache specialist.
Later, we compared preventive measures sug-
gested to patients by both groups of  neurology pro-
viders. On the whole prophylaxis was commenced 
in 82.1% of  children with chronic migraine. Advice 
regarding lifestyle modifications, for example, hydra-
tion, sleep, exercise, and use of  caffeine was equally 
offered to patients under the care of  non-headache 
specialists and the headache specialist. There is evi-
dence that all of  the above play a modifying role in 
migraine pathogenesis.23-25 While management of  a 
migraine in adults has been relatively well-defined 
by the American Academy of  Neurology guidelines, 
first established in 2000, guidelines for the manage-
ment of  a pediatric migraine were established later 
with significant extrapolation from adult data.26,27 
There was marked variation in the preventive treat-
ment of  migraine in children until the results of  the 
CHAMP study in 2016 that provided high-quality 
evidence that placebo was comparable to use of  com-
monly used prescription drugs.28 The lack of  ran-
domized controlled trials in children often leads to 
use of  nutraceuticals or prescription drugs that lack 
high-quality evidence to support their efficacy.29-31 In 
our study, the non-specialists favored natural supple-
ments which may in fact be non-inferior to prescrip-
tion drugs in children with chronic migraine.28
Short-term follow-up noted no difference in out-
comes as measured by a reduction in headache days 
between children treated by the headache specialist and 
those treated by non-headache specialists. We used a 
single measure to evaluate satisfaction with treatment 
and arbitrarily defined "mild-moderate" and "signifi-
cant” improvement for purposes of this study. We used 
the documentation of the physician in the electronic 
records, which in turn depended on the recall bias of 
the child and the parents.
LIMITATIONS
We relied on documentation in the electronic medi-
cal record to assess why imaging was performed despite 
a reassuring clinical neurological examination and lack 
of atypical historical features. In most instances, the 
reason was not documented, which then by default 
was categorized as “imaging performed due to paren-
tal request.” We did not analyze if  most imaging was 
obtained primarily in preschool age children. The in-
cidence of incidental findings was higher than other 
studies involving children with a headache.32
In some instances, triptans were prescribed, but 
for reasons that were not clearly documented in the 
electronic record, the medication was not being used. 
Potential reasons may include lack of insurance cover-
age, parents’ inability to obtain the medication or lack 
of knowledge regarding when to administer it to their 
child, or inability of the child to swallow medication in 
pill format (the only form approved for use in the bulk 
of our patients).
We did not analyze the short-term outcomes of 
children who received botulinum toxin, complemen-
tary treatments, such as acupuncture/ cognitive behav-
ior therapy, or those who used transcranial magnetic 
stimulation devices in addition to “standard” prophy-
lactic agents.
Follow-up of children who were being treated at 
the headache clinic vs the non-headache specialist 
clinic was conducted for an average period of 3 months, 
which may not be a sufficient length of time to study 
the differences. Since an objective measure such as the 
PedMIDAS score or headache diary was not available 
in many instances, these measures that could have pro-
vided meaningful differences, could not be utilized as 
a comparative tool to study the two groups. The retro-
spective nature of the study and recollection bias fur-
ther affects the results with respect to improvement in 
headache days.
Most importantly, this study confines itself  to the 
experiences of a single center where the practice pat-
terns of a single headache specialist are analyzed. There 
are inherent practice variations between headache spe-
cialists, depending on the location of their practice, in-
dividual training and most importantly due to lack of 
strong evidence favoring one drug over another with 
respect to prophylaxis. Therefore, the generalizability 
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of the findings of the study is limited. We would espe-
cially like to highlight that children who were evaluated 
by the headache specialists vs non-specialists were not 
matched with respect to duration or severity of symp-
toms and therefore the results must be interpreted in 
light of this limitation. Pooled experiences of pediatric 
headache specialists compared to non-headache spe-
cialists, across a variety of health care settings will be 
valuable in understanding care that is being provided 
to children with migraine.
CONCLUSIONS
We studied a sample of children with pediatric 
migraine and noted that referral to child neurology 
occurred after a year of the onset of symptoms in many 
cases. Imaging appears to be commonly recommended 
by both non-headache specialists and headache spe-
cialists in children with migraine, with little benefit in 
most instances. The headache specialist was more likely 
to use triptans, while non-headache specialists and the 
headache specialist started prophylaxis at similar rates 
in eligible participants. Outcomes in the short term, 
using limited parameters, were not statistically different 
whether children were being managed by the headache 
specialist or the non-headache specialists.
We believe our study sample is a representative of 
children referred to pediatric hospitals for manage-
ment of migraine. Since not all children who are seen 
at tertiary care institutions are evaluated by pediatric 
headache specialists, we sought to establish differences 
in treatment plans between the 2 groups of physicians. 
The generalizability of our study to larger groups of 
children, who receive care in a variety of medical set-
tings is yet to be established.
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